D Orazio & Associates Inc. Decreases Stock Holdings in Haleon plc (NYSE:HLN)

D Orazio & Associates Inc. cut its holdings in Haleon plc (NYSE:HLN) by 14.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,294 shares of the company’s stock after selling 1,677 shares during the quarter. D Orazio & Associates Inc.’s holdings in Haleon were worth $106,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in Haleon by 8.8% during the first quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company’s stock valued at $131,000 after purchasing an additional 1,041 shares during the last quarter. Addison Advisors LLC raised its position in shares of Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after buying an additional 1,106 shares in the last quarter. Simplicity Wealth LLC lifted its holdings in shares of Haleon by 7.9% in the 1st quarter. Simplicity Wealth LLC now owns 15,482 shares of the company’s stock valued at $159,000 after acquiring an additional 1,135 shares during the last quarter. Haverford Trust Co grew its position in Haleon by 5.0% in the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock worth $247,000 after acquiring an additional 1,233 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in Haleon by 5.9% in the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company’s stock worth $212,000 after acquiring an additional 1,236 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

HLN has been the subject of several analyst reports. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, BNP Paribas raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, May 27th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Down 1.3%

NYSE:HLN opened at $10.87 on Monday. The company has a market cap of $48.90 billion, a price-to-earnings ratio of 31.96, a price-to-earnings-growth ratio of 2.82 and a beta of 0.31. Haleon plc has a twelve month low of $8.25 and a twelve month high of $11.42. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a fifty day simple moving average of $10.61 and a 200-day simple moving average of $10.08.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.